Growth in this market is primarily driven by the rising focus on preventive healthcare, significant increase in venture capital investments and benefits of digital therapeutics

[204 Pages Report] The global digital therapeutics market is projected to reach USD 13.1 billion by 2026, at a CAGR of 31.4% during the forecast period.

Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=51646724

Report Scope and Market Segmentation:

Report Metric

Details

Market Size Available for Years

2019–2026

Base Year Considered

2020

Forecast Period

2022–2026

Forecast Units

Value (USD Billion)

Segments Covered

Sales Channel, Application, and Region

Geographies Covered

North America, Europe, APAC, Latin America and Middle East & Africa

Companies Covered

Noom (US), Livongo Health (US), Omada Health (US), WellDoc (US), Pear Therapeutics (US), Proteus Digital Health (US), Propeller Health (US), Akili Interactive Labs (US), Better Therapeutics (US), Happify (US), Kaia Health (Germany), Mango Health (US), Click Therapeutics (US), Canary Health (US), Wellthy Therapeutics (India), Cognoa (US), Ayogo Health (Canada), Mindstrong Health (US), 2Morrow (US), Ginger (US) BehaVR (US), Mindable Health (Germany), Virta Health (US), Hinge Health (US), and Doktor.se (Sweden)

 

Treatment/care-related applications form the largest segment of the market, by application.

Based on application, the digital therapeutics market is segmented into preventive and treatment/care-related applications. The treatment/care-related applications segment held the largest share of 82.3% of this market

The B2B segment is the largest and fastest-growing segment of the market during the forecast period.

Based on the sales channel, the digital therapeutics market is segmented into business-to-customer (B2C) and business-to-business (B2B). the B2B segment accounted for the largest share of 86.3% of the digital therapeutics market.

North America commanded the largest share of the digital therapeutics market.

North America held the largest share of the market, followed by Europe. The market in North America is also expected to grow at the highest CAGR of 32.2%. Factors such as the influx of new start-ups, increasing investments in digital therapeutics, improvements in the reimbursement structure for digital therapeutics, and government initiatives to support technological advancements drive market growth in this region.

Noom (US)

Noom (US) is one of the leading providers of the digital therapeutics market. The company provides best-in-class solutions for weight management, hypertension prevention, hypertension management, diabetes prevention, diabetes management, and comorbidities of hypertension and diabetes. The company adopts organic as well as inorganic strategies to strengthen its position in the digital therapeutics market.

Request for Sample Pages @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=51646724